Artificial Intelligence (AI) is transforming commercial healthcare from vision to reality. Today, AI-powered solutions are driving measurable improvements in patient outcomes and commercial performance - especially for emerging biopharma (EBP) organizations focused on rare and complex diseases. These conditions are often marked by diverse symptoms and limited treatment options, while posing significant clinical and financial challenges. By harnessing AI and analytics, organizations can more quickly identify at-risk populations, map prescriber and payer landscapes, and unlock new pathways to successful commercialization. As a result, more effective therapies are reaching the right patients faster to improve lives while advancing business goals.

Smarter Engagement with Healthcare Providers

AI is transforming how field teams connect with healthcare providers, making every interaction more targeted and effective. Virtual assistants and predictive targeting tools empower teams to prioritize outreach, tailor messaging, and optimize scheduling. By integrating data, trends and channel preferences with advanced analytics, AI-powered systems can deliver actionable insights—reducing friction and ensure every engagement is relevant and timely.

AI-driven segmentation models can pinpoint top prescribers for niche therapies like oncology, allowing emerging biopharma commercial teams to focus their efforts where they can have the greatest impact. These sophisticated models also identify patients who are likely to change therapy due to mismanaged or misunderstood adverse events (AE). Early intervention guided by AI insights can mean the difference between a patient continuing an effective therapy with the right strategy or discontinuing therapy altogether. This targeted approach not only improves patient outcomes, but also maximize the commercial success of innovative therapies and mechanisms of action (MOA).

Accelerating Market Access and Compliance

Regulatory hurdles and market access complexities can slow the delivery of breakthrough therapies, but AI is challenging this by streamlining access to rare disease markets where data is limited. AI is reshaping this process by automating AE monitoring and analyzing real-world evidence, to build stronger safety profiles and support fast approvals for new therapies.

AI also supports the modeling of value-based contracts and outcome simulations, helping organizations and healthcare providers (HCPs) make informed decisions about therapy options and reimbursement strategies. Internal teams use these capabilities to guide clients through complex payer landscapes and to optimize launch strategies.

Recent case studies demonstrate the power of AI in identifying underserved patient populations, like uncovering 56% more patients with social determinants of health (SDOH) than traditional methods. By accurately measuring and curating SDOH data, commercial strategies can refocus physicians and healthcare specialists to better serve those who might otherwise be overlooked—ensuring equitable access to care and improved outcomes for vulnerable groups.

Unlocking Faster Approvals and Better Patient Outcomes

AI is empowering HCPs to deliver better care by enabling earlier and more accurate identification of patients with rare and complex diseases. Advanced analytics and machine learning can detect at-risk or misdiagnosed individuals for early intervention and guide patients towards effective therapies—leading to faster diagnoses, timely treatments, for patients that might otherwise be overlooked.

AI models have been used to identify misdiagnosed type 1 diabetes patients, allowing providers to intervene before costly and life-threatening complications arise. By flagging these cases early, HCPs can ensure patients receive the right therapy and management strategy, dramatically improving their quality of life.

Turning Complex Data into Decisions

Today, advanced AI tools have transformed healthcare, enabling teams to bring together diverse data inputs efficiently and securely. For internal teams, this means faster access to insights, better alignment across functions, and more agile client delivery. The ability to link patient-level data across multiple sources, using AI managed privacy tokens to resolve partial matches and minimize false positives, is creating a more accurate view of the patient journey.

Generative AI and natural language processing (NLP) have become essential for interpreting and leveraging big data in life sciences. Proprietary models, trained on life sciences-specific terminology and workflows, deliver precise, contextual insights. Large language models (LLMs) and NLPs help interpret critical data without the need for time consuming Structured Query Language (SQL) development or custom data extracts.

The result is a new era of AI-powered conversational analytics, where business users can interact with complex commercial data using plain language. These AI-powered platforms provide explainable, governed answers, empowering teams to test scenarios, identify patients, target prescribers, and refine payer strategies rapidly.

AI and advanced analytics are transforming life sciences by enabling emerging biopharmas to identify hard-to-diagnose conditions, deliver timely and accurate care, and guide both patients and HCPs in managing adverse events with the most effective therapies. AI streamlines complex treatment logistics, payer interactions, and reimbursement processes, driving results that were previously out of reach.

IQVIA’s EBP Analytics team streamlines the launch of critical therapies in rare and complex disease areas by reducing the time and effort from data to insights, driving better outcomes for patients and providers.

To learn more about IQVIA's approach to AI and advanced analytics, we encourage you to read Are Life Sciences Behind in the Adoption of AI? This blog explores the challenges that have slowed AI adoption in life sciences, including complex data, regulatory requirements, and the need for trustworthy insights. It also highlights how modern analytics and AI-enabled data strategies can help organizations generate faster, more informed business insights while improving efficiency and decision-making.